Skip to content
Bendroflumethiazide
Corzide, Naturetin (bendroflumethiazide) is a small molecule pharmaceutical. Bendroflumethiazide was first approved as Naturetin-2.5 on 1982-01-01. It is used to treat edema, heart failure, hypertension, and nephrotic syndrome in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bendroflumethiazide
Tradename
Company
Number
Date
Products
NATURETIN-2.5Bristol Myers SquibbN-012164 DISCN1982-01-01
1 products
NATURETIN-5Bristol Myers SquibbN-012164 DISCN1982-01-01
1 products
NATURETIN-10Bristol Myers SquibbN-012164 DISCN1982-01-01
1 products
Hide discontinued
Bendroflumethiazide
+
Nadolol
Tradename
Company
Number
Date
Products
CORZIDEKing PharmaceuticalsN-018647 DISCN1983-05-25
2 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
nadolol and bendroflumethiazideANDA2016-04-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
edemaD004487R60.9
heart failureEFO_0003144D006333I50
hypertensionEFO_0000537D006973I10
nephrotic syndromeEFO_0004255D009404N04
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
C03: Diuretics
C03A: Low-ceiling diuretics, thiazides
C03AA: Thiazides, plain
C03AA01: Bendroflumethiazide
C03AB: Thiazides and potassium in combination
C03AB01: Bendroflumethiazide and potassium
C03E: Diuretics and potassium-sparing agents in combination
C03EA: Low-ceiling diuretics and potassium-sparing agents
C03EA13: Bendroflumethiazide and potassium-sparing agents
HCPCS
No data
Clinical
Clinical Trials
95 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AlcoholismD000437EFO_0003829F10.12864118
Cerebral palsyD002547G8012136
Gastroesophageal refluxD005764EFO_0003948K211124
Muscle spasticityD009128HP_0001257123
PainD010146EFO_0003843R52123
Alcohol withdrawal deliriumD000430EFO_10008001113
StrokeD020521EFO_0000712I63.911
HemiplegiaD006429G81.011
Overactive urinary bladderD053201EFO_1000781N32.8111
Lower urinary tract symptomsD059411EFO_000800811
Show 6 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple sclerosisD009103EFO_0003885G35134
AnalgesiaD000698111
Acute painD059787R52111
Female genital diseasesD005831EFO_0009549N85111
LeukemiaD007938C9511
Myelodysplastic syndromesD009190D4611
NeoplasmsD009369C8011
Myeloproliferative disordersD009196D47.111
LymphomaD008223C85.911
Lymphoproliferative disordersD008232Orphanet_2442D47.911
Show 5 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Tobacco use disorderD014029F1733
Liver cirrhosisD008103EFO_0001422K74.0123
Cocaine-related disordersD019970F1433
Spinal cord injuriesD013119EFO_1001919112
Fragile x syndromeD005600Q99.2112
Muscle crampD009120HP_0003394112
Marijuana abuseD002189EFO_0007191F1222
Anxiety disordersD001008EFO_0006788F41.111
Alcohol drinkingD000428EFO_000432911
Alcoholic liver cirrhosisD008104EFO_1000802K70.3111
Show 6 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients314
Substance-related disordersD019966EFO_0003890F1311
Neonatal abstinence syndromeD009357EFO_0005799P96.111
Autistic disorderD001321EFO_0003758F84.011
Cheyne-stokes respirationD002639R06.311
Ataxia telangiectasiaD001260Orphanet_100G11.311
PharmacokineticsD01059911
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Migraine disordersD008881EFO_0003821G4311
HeadacheD006261HP_0002315R5111
ArthritisD001168EFO_0005856M05-M1411
TendinopathyD052256EFO_1001434M77.911
SynovitisD013585EFO_0008997M67.511
SpasmD013035M62.8311
RadiculopathyD011843M54.111
GoutD006073EFO_0004274M1011
Feeding and eating disordersD001068F5011
Bulimia nervosaD052018EFO_0005204F50.211
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBENDROFLUMETHIAZIDE
INNbendroflumethiazide
Description
Bendroflumethiazide is a sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group. It has a role as a diuretic and an antihypertensive agent. It is a benzothiadiazine and a sulfonamide.
Classification
Small molecule
Drug classdiuretics (thiazide derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NC(Cc1ccccc1)NS2(=O)=O
Identifiers
PDB
CAS-ID73-48-3
RxCUI1369
ChEMBL IDCHEMBL1684
ChEBI ID3013
PubChem CID2315
DrugBankDB00436
UNII ID5Q52X6ICJI (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,315 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
34,943 adverse events reported
View more details